Neither mutation nor gene expression change in JAK1, JAK2, B2M, HLA-A, HLA-B, and HLA-C was observed (Fig. S1 A) between pre- and post-treatment tumor samples, which were previously indicated to be associated with resistance to PD-1 antibody treatment in melanoma (Zaretsky et al., 2016; Shin et al., 2017). This evidence concerns the gene PDCD1 and neoplasm.